ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Craig H. Selzman
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selzman, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selzman, C. H.
Related Collections
Right arrow Mechanical Circulatory Assistance
Right arrowRelated Article

Ann Thorac Surg 2006;82:1418-1419
© 2006 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Invited commentary

Craig H. Selzman, MD

Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, 3040 Burnett Womack, CB 7065, Chapel Hill, NC 27599

(Email: selzman@med.unc.edu).

The first 20% of the full text of this article appears below.

The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial investigating lifetime use of left ventricular assist devices (LVAD) in non-transplant-eligible patients with end-stage heart disease was performed between 1998 and 2001 using the HeartMate vented electric (VE) device (Thoratec Corp, Pleasanton, CA). This seminal study rigorously and prospectively established new standards for survival, quality of life, and adverse events in this severely ill patient population.

Despite the favorable results for LVAD versus optimal medical management, REMATCH is often criticized by the medical community: few patients survived more than 2 years secondary to high rates of adverse events (infection, bleeding, neurologic) and device failure (35% at 2 years). As . . . [Full Text of this Article]


Related Article

Improved Mechanical Reliability of the HeartMate XVE Left Ventricular Assist System
Francis D. Pagani, James W. Long, Walter P. Dembitsky, Lyle D. Joyce, and Leslie W. Miller
Ann. Thorac. Surg. 2006 82: 1413-1418. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.